Search Results

• Human Neurophysiology in Epilepsy Patients

  Human Neurophysiology in Epilepsy Patients

• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/​or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  AAML1831 - A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

• Surveillance or Treatment of Patients w/Germ Cell Tumors

  A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

• A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care

  A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care

• Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients with Chronic Heart Failure

  Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients with Chronic Heart Failure

• A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

• Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

• SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin

  SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin

• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

• Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

  AGCT1532 - Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours